Abstract
Multiple regression analysis revealed co-existence of thrombophilic mutations as independent risk factor for TE recurrence p=0.019. The probability of recurrence in women harboring at least 2 out of 3 thrombophilic mutations is 4.703 times higher [Exp(B)=4.703(adjusted OD), 95%CI:1.293-17.114] compared to the others. Comment: A periodb6 months of COC intake is significantly associated with higher recurrence rates. Moreover, although when MTHFR tested alone isn't associated with recurrence, its' co-existence with FVLeiden increases recurrence rates significantly. Last but not least, co-existence of at least 2 out of 3 thrombophilic mutations raises a 5fold risk for recurrence.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
